Pricing a Placement While a Customer Exit Is Still Undisclosed
Teluk Data Centres Bhd (TDC) is a Main Market-listed operator of two hyperscale data centres with a market capitalisation of RM2.4 billion. On 14 April the board mandates your corporate finance team to place up to 10% of TDC's issued shares - approximately 88 million shares - with Malaysian and Singapore institutions to part-fund a RM300 million expansion. Pre-marketing on 15 and 16 April produces indications of interest at RM2.60 to RM2.75 from six funds, and pricing is scheduled for 21 April. TDC's first-quarter results, showing revenue up 9%, were announced on 12 April. On the evening of 17 April the managing director tells you, alone, that TDC's largest customer - 35% of FY2024 revenue and the anchor tenant for the new build - will announce next week that it will not renew its lease beyond 2026. He says the position is 'commercially sensitive and not yet certain', that the placement must be priced before the customer goes public, and that the matter is to stay between the two of you.
1. What is the status of the customer information, and what must happen before the placement is priced? Sequence the steps.
Read the worked answer
Status of the information. It is almost certainly inside information: information not generally available which a reasonable person would expect to have a material effect on the price of TDC shares. The MD's caveats are not the test. The contract is not a small one - 35% of revenue, and the anchor tenant for the very expansion the placement is funding. 'Not yet certain' may affect the precise wording of the announcement but not the obligation to deal with it.
Sequence.
- Escalate immediately, on 17 April. The board, the audit committee chair and the company secretary must be told. The MD's instruction that the matter stay between the two of you has no effect on the firm's regulatory duties and should be rejected in writing.
- Board consideration and immediate announcement. The board must assess and announce through Bursa as soon as practicable. The listing requirements require immediate public disclosure of material information; commercial convenience to complete a fundraising is not a permitted reason to delay. Selective disclosure to any fund before announcement is prohibited.
- Suspend pricing. The 21 April pricing cannot proceed on information the buyer pool does not have.
- Re-market after announcement. The six funds can be re-approached once the announcement is out, with re-set guidance and fresh indications. The price will move; that is the point of an efficient market.
- Warranties. The placement agreement must contain an accurate no-material-undeclared-information warranty given at pricing. You cannot ask for or accept that warranty while you know it is untrue.
If the board refuses to announce, the placement cannot proceed with your firm as agent.
2. What are your firm's obligations in relation to the six funds that have already given indications, and in relation to the MD's confidentiality request?
Read the worked answer
As at 17 April, no tipping has occurred. The indications were gathered before you learned of the customer exit, so the funds are not restricted and the firm has not yet breached anything. What matters is what happens next.
Do not contact the funds again until the information is public. Any further soundings from now on would amount to communicating inside information to people who may act on it, and would taint the placement. If absolutely necessary to stop a fund from dealing, a formal wall-crossing can be used - a documented approach, explanation of the restriction, and a written undertaking not to deal or communicate. Do not do it informally, and do not do it at all if a suspension plus announcement can be achieved quickly.
The confidentiality request. The MD's instruction does not bind the firm and cannot override the firm's obligations. Respond in writing: the firm will keep the information confidential and will not trade or tip, but it must be escalated internally and to the board, and it will be announced if the board does not act.
Internal controls. Activate the restricted list for TDC immediately, extend it to the firm's proprietary and wealth books, and remind staff and connected persons not to deal in TDC securities. Keep a dated record of who knew what and when - this includes your escalation note to the board.
If the board will not announce. Decline to act as placement agent, and consider whether the circumstances require a report to the SC. Walking away in writing is the defensible step.
3. The MD suggests cutting the placement to 5% and pricing on 21 April 'because 5% is not material'. Evaluate the proposal.
Read the worked answer
The proposal confuses the size of the transaction with the materiality of the information. They are different questions and both need answering.
Size does not cure materiality. Materiality is judged by the expected effect of the information on the share price, not by the number of shares being sold. A customer representing 35% of revenue and anchoring the new build is material whether TDC places 88 million or 44 million shares. Shrinking the placement reduces the amount raised but leaves the disclosure problem entirely intact - and half-funding a RM300 million expansion does not answer the commercial problem the company actually has.
Nor is the general mandate the issue. The 10% limit is a shareholder authorisation question; a smaller placement sits inside the mandate on either figure, but that is irrelevant to whether the market is properly informed.
The real effect of the proposal. Selling shares to institutions on 21 April at RM2.60 to RM2.75, knowing what the buyer does not know, is the harm the insider dealing and disclosure rules exist to prevent. The buyers would be paying a price that does not reflect the news and would have an obvious claim. For the firm, it converts a manageable compliance problem into a live dispute about what the adviser knew and when.
What to say. The size is a separate decision the board can revisit for funding reasons. The sequence is not negotiable: announce, then market, then price. If the timing is commercially painful, the answer is to reconsider the fundraising - a short bridge facility, a smaller placement after announcement, or an accelerated bookbuild launched after the disclosure - not to price into an uninformed market.